CHMP Upholds Negative Opinion For The EU Application For Cimzia® In The Treatment Of Crohn’s Disease

UCB announced today that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has rejected the appeal following CHMP refusal of the Marketing Authorization Application (MAA) for Cimzia® (certolizumab pegol) in the treatment of patients with Crohn’s disease, a chronic and debilitating inflammatory disease.

More: continued here

Filed under: Crohn on April 2nd, 2008